26/01/2018
« Introduction: Journal publishers increasingly offer governmental and charitable research funders the option to pay for open access with a Creative Commons Attribution (CC BY) licence, which allows sharing and adaptation of published materials for commercial as well as non-commercial use. The Open Access Scholarly Publishers Association recommends this licence as the least restrictive Creative Commons licence available. We set out to investigate whether pharmaceutical companies are offered the same options. (…) »
Continuer sur le site de la source > biorxiv.org, Tim Ellison, Tim Koder, Laura Schmidt, Amy Williams, Christopher Winchester, https://doi.org/10.1101/250613, 22 janvier 2018